- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04423848
Home Hospital for Lymphoma
Supportive Oncology Care at Home Intervention for Patients With Lymphoma
Studienübersicht
Detaillierte Beschreibung
This research study is a single arm pilot Feasibility Study, which is the first-time investigators are examining this hospital at home intervention for patients with lymphoma.
The research study procedures include screening for eligibility, questionnaires, remote patient monitoring (e.g. patient-reported symptoms and home monitored vital signs) and home-based supportive care (e.g. visits to patients' homes to address and manage any concerning issues identified), and interviews of participants, caregivers, and clinicians asking their perceptions of the Home Hospital for Lymphoma program.
Participants will include 3 groups:
Enrolled participants receiving the hospital at home intervention, caregivers of participants, and clinicians.
Participants will be in the research study for about six months after consent. It is expected that up to 38 participants will take part in this research study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 18 or older
- Receiving their lymphoma care with curative intent at MGH (treatment intent based upon chemotherapy order in the electronic medical record)
- Hemodynamically stable during the first 24 hours of hospital admission at MGH
- Residing within the designated geographic area for MGH Home Hospital Service (an approximately 10-mile radius from MGH)
- Able to communicate and respond to questionnaires in English
- Lives with a family member or a friend who supports the patient at home
- Deemed eligible for supportive oncology care at home based on the MGH Home Hospital clinician evaluation
Exclusion Criteria:
- Those admitted to the intensive care unit
- Have high oxygen requirement (FIO2 > 0.4)
- Experience active angina or cardiac arrythmias
- Have a planned inpatient surgical or interventional procedure
- Have uncontrolled psychiatric illness or impaired cognition that prohibits complying with the study procedures
- Have uncontrolled pain requiring intravenous pain medications
- Those deemed ineligible based on the Home Hospital Service clinician evaluation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Home Hospital for Lymphoma
The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
|
Remote monitoring and home-based care designed for hospitalized patients with lymphoma
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
enrollment rate
Zeitfenster: 1 year
|
The primary endpoint is feasibility.
The proposed intervention will be deemed feasible if at least 60% of eligible patients are enrolled in the study
|
1 year
|
retention rate
Zeitfenster: 1 year
|
The primary endpoint is feasibility.
The proposed intervention will be deemed feasible if those enrolled patients complete at least 60% of daily patient-reported symptom assessment.
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Akzeptanz des Eingriffs
Zeitfenster: 1 Jahr
|
Qualitative Akzeptanzbewertungen von Patienten, Pflegekräften und Ärzten, die über individuelle Ausgangsinterviews zur Akzeptanz (d. h.
Nützlichkeit, Wirksamkeit und Relevanz der Intervention) von Patienten, pflegenden Angehörigen und Ärzten.
Die Intervention gilt als akzeptabel, wenn ≥ 60 % der Patienten, pflegenden Angehörigen und Ärzte berichten, dass die Intervention hilfreich war.
|
1 Jahr
|
Rates of completion of daily vital signs
Zeitfenster: 1 year
|
Proportion of participants that complete daily reporting of vital signs during their home hospital admission.
|
1 year
|
Rates of Adverse Events
Zeitfenster: 1 year
|
The rates of Adverse Events and Serious Adverse Events that are judged by the treating lymphoma clinician to be at least possibly related to the study intervention.
|
1 year
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Symptom burden (Edmonton Symptom Assessment System-revised - ESAS-r)
Zeitfenster: 1 year
|
Change in participants' symptom burden as measured by the ESAS-r throughout the study.
The ESAS-r ranges 0-10 for each symptom with higher scores indicating worse symptom burden.
|
1 year
|
Psychological distress (Hospital Anxiety and Depression Scale - HADS)
Zeitfenster: 1 year
|
Change in psychological distress as measured by the HADS, with subscale ranges from 0-21 with higher scores indicating worse psychological distress.
|
1 year
|
Quality of life (Functional Assessment of Cancer Therapy-General - FACT-G)
Zeitfenster: 1 year
|
Change in quality of life as measured by the FACT-G throughout the study, with range of 0-108 and higher scores indicating better quality of life.
|
1 year
|
Length of home hospital admission
Zeitfenster: 1 year
|
Number of days the participant receives home hospital care through the home hospital program.
|
1 year
|
Number of home visits
Zeitfenster: 1 year
|
Number of home visits required, their average duration, the issues addressed at home, and the interventions delivered to participants at their home.
|
1 year
|
Number of phone calls
Zeitfenster: 1 year
|
Number of phone calls required per participants as well as the average duration of these calls.
|
1 year
|
Number of urgent visits
Zeitfenster: 1 year
|
The number of urgent visits to clinic per participant and the proportion of participants who have an urgent visit to clinic.
|
1 year
|
Number of emergency department (ED) visits The number of imaging tests ordered during home hospital admission
Zeitfenster: 1 year
|
The number of emergency department (ED) visits per participant and the proportion of participants who have an ED visit.
|
1 year
|
Number of hospital readmissions
Zeitfenster: 1 year
|
The number of hospital readmissions in 30 days per participant and the proportion of participants who have a hospital readmission within 30 days.
|
1 year
|
Number of imaging studies
Zeitfenster: 1 year
|
The number of imaging studies obtained per participant during the Home Hospital admission.
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 19-613
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
Klinische Studien zur Home Hospital for Lymphoma
-
Vidya RamanAbgeschlossen
-
Istanbul University - Cerrahpasa (IUC)AbgeschlossenRheumatische Erkrankungen | Nur Kind | ArmTruthahn